Evidence map›Paper›PMID 39473505›Full record

ReviewFrontiers in endocrinology2024

Opportunities for digitally-enabled personalization and decision support for pediatric growth hormone therapy.

Paul Dimitri, Paula van Dommelen, Indraneel Banerjee, Riccardo Bellazzi, Marta Ciaccio, Antonio de Arriba Muñoz, Sandro Loche, Azriyanti Anuar Zaini, Ammar Halabi, Merat Bagha and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Paul DimitriUniversity of Sheffield, Western Bank, Sheffield, United Kingdom.
Paula van DommelenDepartment of Child Health, The Netherlands Organization for Applied Scientific Research TNO, Leiden, Netherlands.
Indraneel BanerjeeRoyal Manchester Children's Hospital, Manchester University Hospitals Foundation Trust, Manchester, United Kingdom.
Riccardo BellazziDepartment of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.
Marta CiaccioEndocrinology Service, National Pediatric Hospital "Prof. Dr. Juan P. Garrahan", Buenos Aires, Argentina.
Antonio de Arriba MuñozPaediatric Endocrinology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Sandro LocheResearch Area for Innovative Therapies in Endocrinopathies, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Azriyanti Anuar ZainiDepartment of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Ammar HalabiGlobal Digital Health, Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.
Merat BaghaTiba Medical Inc., Beaverton, OR, United States.
Ekaterina KoledovaGlobal Medical Affairs Cardiometabolic & Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Smart technologies and connected health are providing opportunities for improved healthcare for chronic conditions. Acceptance by healthcare professionals (HCPs) and patients is crucial for successful implementation. Evidence-based standards, technological infrastructure and regulatory processes are needed to integrate digital tools into clinical practice. Personal health records provide continuity and aid decision-making, while machine-learning algorithms may help in optimizing therapies and improving outcomes. Digital healthcare can negate geographical barriers, enabling patients in remote areas to access specialist endocrine expertise. We review available and developing digital tools to manage care for patients requiring growth hormone (GH) therapy for growth failure conditions. GH is most often administered via daily injections over several years; continuous adherence is necessary but may become insufficient. Future development and integration of electronic platforms for GH therapy requires involvement of all stakeholders in design-thinking approaches and human-factor testing. Growzen Connect is an innovative digital ecosystem designed to increase the management and monitoring of GH therapy, comprising the easypod device and connected mobile apps. It provides a real-time overview of a patient's therapy, including adherence and growth response, which aids decision-making by HCPs and empowers patients to engage in their therapy journey. Incorporating prediction models for adherence and growth in the ecosystem helps patients build treatment habits and allows issues to be addressed in a timely fashion. A connected ecosystem for GH therapy can enhance outcomes and empower patients, fostering a collaborative and patient-centered approach that is more proactive, beyond the traditional clinic-based approach.

Indexed as

Human Growth HormoneChildDecision Support Systems, ClinicalGrowth DisordersHumansPrecision MedicineTelemedicineHuman Growth Hormonedecision supportdigitalgrowth hormonepediatrictechnology

Identifiers

PMID39473505
PMCPMC11518754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.